Telavancin (Vibativ) for gram-positive skin infections

Medical Letter on Drugs and Therapeutics

Volumn 52, Issue 1329, 2010, Pages 1-2

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CEFALEXIN; CEFAZOLIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DICLOXACILLIN; LINEZOLID; NAFCILLIN; OXACILLIN; TELAVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; VIBATIV;

ANTIBACTERIAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG ADMINISTRATION ROUTE; DRUG COST; DRUG HALF LIFE; DRUG MECHANISM; FETUS WEIGHT; FOAMY URINE; GRAM POSITIVE INFECTION; HUMAN; LIMB DEFORMITY; NAUSEA; NONHUMAN; PREGNANCY TEST; QT PROLONGATION; SIDE EFFECT; SKIN INFECTION; TASTE DISORDER; VOMITING;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; SKIN DISEASES, BACTERIAL; TREATMENT OUTCOME;

EID: 75149122568     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. LD Saravolatz et al. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 2009; 49:1908.
2. ME Stryjewski et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005; 40:1601.
3. ME Stryjewski et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006; 50:862.
4. ME Stryjewski et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46:1683.
5. E Rubinstein et al. Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: the ATTAIN studies. In: 18th European Congress of Clinical Microbiology and Infectious Diseases; April 19, 2008; Barcelona, Spain. Abstract 075.
6. CYP3A and drug interactions. Med Lett Drugs Ther 2005; 47:54.
7. Arizona Center for Education and Research on Therapeutics. Drugs that prolong the QT interval and/or induce torsades de pointes ventricular arrhythmia. Available at www.azcert.org. Accessed December 21, 2009.